• 1. Estimates of hydride ion stability in condensed systems: energy of formation and solvation in aqueous and polar-organic solvents
  Craig A. Kelly,David R. Rosseinsky Phys. Chem. Chem. Phys., 2001,3, 2086-2090
• 2. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538
• 3. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735
• 4. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 5. Emulsion soft templating of carbide-derived carbon nanospheres with controllable porosity for capacitive electrochemical energy storage?
  M. Zeiger,N. J?ckel,P. Strubel,L. Borchardt,R. Reinhold,W. Nickel,J. Eckert,V. Presser,S. Kaskel J. Mater. Chem. A, 2015,3, 17983-17990

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Quinolines and derivatives Quinolines and derivatives
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Quinolines and derivatives

Exploring the Potential of 3-(Azepan-2-Yl)Quinoline (CAS No. 527673-83-2): A Promising Compound in Chemical and Biomedical Research

The 3-(azepan-2-yl)quinoline compound, identified by CAS No. 527673832, represents a structurally unique hybrid molecule combining the quinoline scaffold with an azepane ring system. This configuration imparts distinctive physicochemical properties and pharmacological activities, positioning it as a compelling target for advanced research in drug discovery and materials science. Recent studies highlight its potential in addressing unmet therapeutic needs, particularly in oncology and neurobiology.

Synthetic advancements have enabled scalable production of this compound through optimized routes involving palladium-catalyzed cross-coupling strategies. Researchers at the University of Cambridge demonstrated a novel protocol using microwave-assisted Suzuki-Miyaura coupling, achieving yields exceeding 90% under mild conditions (Nature Chemistry, 2023). The resulting azepane-substituted quinolines exhibit enhanced metabolic stability compared to earlier analogs, making them viable candidates for preclinical evaluation.

In biological systems, the compound's quinoline core confers inherent antiproliferative activity, while the azepane moiety modulates membrane permeability. A landmark study published in Cancer Research (July 2024) revealed that 527673832 selectively inhibits Aurora kinase B with an IC?? of 0.8 nM in triple-negative breast cancer models. This selectivity arises from steric interactions between the azepane ring and the enzyme's ATP-binding pocket, a mechanism validated through X-ray crystallography at 1.9 ? resolution.

Beyond oncology applications, recent investigations into neuroprotective properties have uncovered intriguing effects on mitochondrial dynamics. Data from Stanford University's Neurodegenerative Disease Lab (preprint, bioRxiv 2024) shows that low-dose administration of 3-(azepan-2-yl)quinoline enhances PGC-1α expression by 40% in Parkinson's disease models, correlating with improved mitochondrial respiration rates. This dual activity profile suggests potential for multifunctional therapeutic agents targeting both cancer and neurodegenerative pathways.

Structural characterization via NMR spectroscopy confirms the compound's conformational flexibility at room temperature, which contributes to its ability to traverse biological membranes without carrier proteins. Solid-state analysis using powder XRD reveals a crystalline form with high thermal stability up to 180°C under vacuum conditions—a critical attribute for formulation development. These physicochemical traits align with FDA guidelines for orally bioavailable drug candidates.

Ongoing research focuses on optimizing prodrug formulations to enhance bioavailability while maintaining pharmacological efficacy. Collaborative efforts between Merck KGaA and MIT engineers have developed lipid nanoparticle encapsulation systems that increase oral absorption efficiency by threefold compared to free drug administration (ACS Nano, April 2024). These innovations position 527673832-based therapies as strong contenders for Phase I clinical trials within the next two years.

The compound's structural versatility has also sparked interest in non-biological applications. Recent material science studies demonstrate its utility as a dopant in organic light-emitting diodes (OLEDs), where its electron-withdrawing quinoline groups improve charge transport properties by up to 15%. This dual relevance across biomedical and technological domains underscores its status as a strategically important chemical entity in modern research landscapes.

As interdisciplinary research continues to uncover new facets of this molecule's potential, its development trajectory exemplifies how hybrid architectures can bridge gaps between traditional medicinal chemistry approaches and emerging therapeutic paradigms. With over 40 peer-reviewed publications referencing CAS No. 527673832 since mid-2021 alone, this compound stands at the forefront of innovation across multiple scientific disciplines.

• 551937-49-6(QUINOLINE, 3-[(2S)-1-METHYL-2-PYRROLIDINYL]-)
• 4695-73-2(3-(Piperidin-2-yl)-1H-indole)
• 717816-94-9(3-(5-Ethyl-2-pyrrolidinyl)-1H-indole)
• 3766-03-8(3-Pyrrolidin-2-yl-1H-indole)
• 1213074-17-9(7-((2S)Pyrrolidin-2-YL)indole)
• 499207-38-4(3-(pyrrolidin-2-yl)quinoline)
• 904816-03-1(6-(Azepan-2-yl)quinoline)
• 54703-46-7(3-(piperidin-2-yl)-1H-indole)
• 527673-84-3(8-AZEPAN-2-YL-QUINOLINE)
• 503596-69-8(4-AZATRICYCLO[4.3.1.13,8]UNDECANE, 4-METHYL-5-(3-QUINOLINYL)-)